Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
PaperCitations, authors & open-access status
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 316 citations, 2023 year and closed oa status.
316
Citations
2023
Year
closed
OA Status